J. Torres-Ruiz1, D. Faz-Muñoz2, N. Hernández-Díaz3, G. Hernandez-Molina4
2018 Vol.36, N°3 ,Suppl.112 - PI 0177, PF 0181
Free to view (click on article PDF icon to read the article)
To assess the use and causes of withdrawal of glucocorticoids and immunosuppressors among patients with primary Sjögren’s syndrome (pSS) in the clinical setting.
We retrospectively reviewed the medical records of 155 pSS patients and registered demographics, glandular/extraglandular features, serological data, cumulative ESSDAI and SSDDI. A single rheumatologist attributed the indication and cause of withdrawal of glucocorticoids and immunosuppressors.
92.2% of the patients were female, mean age 57.4±14.7 years and median follow-up 11 years. One hundred and four (67%) patients received glucocorticoids and/or immunosuppressors: 3.8% only glucocorticoids, 43.9% only immunosuppressors and 56.5% their combination. The most used drugs were antimalarials (46.4%), prednisone (36.7%), azathioprine (AZA) (23.8%) and methotrexate (MTX) (18%). At the multivariate analysis, the presence of non-erosive arthritis OR 5.02 (95% CI 1.74–14.47, p=0.003) and the median cumulative ESSDAI score OR 1.10 (95% CI 1.03–1.17, p=0.002) were associated with the use of these drugs. The causes of withdrawal were: 39% improvement, 35.2% patient’s own decision, 18.1% toxicity and 11% lack of efficacy. We found toxicity in 14.2% MTX users, 9.7% for AZA, 9.7% for antimalarials and 7.6% for cyclophosphamide.
More than half the patients received glucocorticoids and/or immunosuppressors and a not negligible number decided on their own to suspend them, alerting physicians of secondary adverse events and tolerability.
PMID: 28421999 [PubMed]
Received: 13/12/2016 - Accepted : 27/02/2017 - In Press: 18/04/2017 - Published: 14/08/2018